(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release
Posted in Business, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged Anti-TL1As, Crohn's disease, in $1.5 Billion Deal, Inflammatory Bowel Disease Treatment, partnership, Paul Hudson, Richard Francis, Sanofi, sustainability, Teva, TEV’574, Ulcerative colitis, wellness
LUXEMBOURG, 11-Oct-2017 — /EuropaWire/ — CVC Capital Partners (“CVC”) today announced that former Allergan executive Anish Mehta will be appointed as CEO of the international women’s health assets portfolio which CVC Fund VI agreed to acquire from Teva Pharmaceutical Industries Ltd … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
